Pre-Approved vs Post-Filing: Which Advertising Compliance Route for Your Product Category?
China’s advertising regulatory landscape has undergone a profound transformation since the landmark 2018 Advertising Law amendments. For foreign businesses entering the Chinese market, the single most critical compliance decision is whether their product advertisements must undergo pre-approval before publication or can proceed under a post-filing (post-approval filing) regime. Getting this wrong can mean fines of up to RMB 1 million, revocation of business licences, and — in the worst cases — criminal liability for false advertising.
This article provides a head-to-head comparison of China’s two main advertising compliance routes. We examine the legal basis, the product categories that trigger each route, the procedural timelines, documentary requirements, and the practical strategies that foreign enterprises use to navigate both systems. By the end, you will have a clear framework for determining which route applies to your product category and how to build compliant advertising campaigns from day one.
1. Understanding the Two-Route Framework
China’s advertising compliance system is not a single, monolithic requirement. Under the Advertising Law of the People’s Republic of China (2018 Revision), the Interim Measures for the Administration of Internet Advertising, and a suite of category-specific regulations (such as Measures for the Administration of Food Advertising and Measures for the Administration of Medical Device Advertising), advertisers must follow one of two distinct pathways:
- Pre-Approval Route (审查批准) — Ad content must be submitted to and formally approved by the relevant government authority before it can be published or broadcast. Approval is typically valid for a fixed period (often one year) and must be renewed.
- Post-Filing Route (事后备案) — Ad content can be published immediately, but the advertiser must file a copy of the advertisement with the relevant authority within a prescribed window (commonly 7–30 days after first publication). The authority retains the right to review and order modifications or removal.
There is also a third, implicit route for ordinary consumer goods with no special regulatory restrictions — but even these must comply with general advertising prohibitions (false claims, comparative disparagement, social-value violations, etc.). For the purposes of this article, we focus on the two formal compliance routes that apply to higher-risk advertising categories.
Key Takeaway: The pre-approval route is mandatory for products and services that directly affect public health, safety, or financial well-being. The post-filing route applies to categories that warrant oversight but do not require prior authorisation. Mistaking one for the other is the single most common compliance pitfall for foreign brands entering China.
2. Product Categories That Require Pre-Approval
Chinese law explicitly enumerates the product categories for which advertisements must be pre-approved. The authoritative list is found in Article 46 of the Advertising Law, supplemented by sector-specific regulations. The following categories always trigger mandatory pre-approval:
2.1 Medical and Healthcare
- Prescription and over-the-counter (OTC) drugs — All pharmaceutical advertisements require approval from the National Medical Products Administration (NMPA) or its provincial counterparts. The approval number must be displayed prominently in the advertisement.
- Medical devices — Class II and Class III medical devices (moderate to high risk) require pre-approval. Class I devices (low risk) may follow a simplified notification process in some provinces.
- Medical treatments and therapies — Advertisements for hospital services, clinical treatments, surgical procedures, and traditional Chinese medicine (TCM) therapies all fall under pre-approval.
2.2 Food and Nutrition
- Health foods (保健食品) — “Health food” (or “functional food”) is a distinct regulatory category in China. Every advertisement must include the mandatory disclaimer: “This product is not a substitute for medicine” and display the health-food approval number.
- Infant formula — Advertisements for infant formula (stage 1 and stage 2) must be pre-approved by the State Administration for Market Regulation (SAMR). Comparative claims against breast milk are strictly prohibited.
- Food for special medical purposes (FSMP) — This emerging category, covering nutritionally complete formulas for patients with specific diseases, requires full pre-approval under regulations jointly administered by the NMPA and SAMR.
2.3 Cosmetics
- Special-use cosmetics (特殊化妆品) — This includes sunscreens, hair dyes, whitening products, anti-hair-loss products, and cosmetics for children under 12. Both the product itself and its advertisements require separate pre-approval.
- General cosmetics (普通化妆品) — Since the 2021 Regulations on the Supervision and Administration of Cosmetics, general cosmetics advertisements follow a post-filing route (see Section 3), unless they make efficacy claims that border on therapeutic — in which case they may be reclassified as special-use.
2.4 Other Regulated Categories
- Alcoholic beverages — Though alcohol advertisements do not require full pre-approval in all cases, certain provinces (e.g., Guangdong, Zhejiang) impose pre-vetting requirements for broadcast and outdoor advertisements.
- Tobacco — Tobacco advertising is effectively banned in all mass media in China. The limited permissible channels (in-store point-of-sale) still require prior approval from local health authorities.
- Pesticides and agricultural chemicals — Advertisements must be pre-approved by the Ministry of Agriculture and Rural Affairs (MARA).
- Fertilisers and feed additives — Subject to pre-approval by MARA if efficacy claims are made.
The Chinese authorities interpret “advertising” broadly. A social media post by a KOL, a product description on a cross-border e-commerce platform like Tmall Global, a WeChat mini-program banner, and even a press release can all be treated as “advertisements” subject to these requirements. Foreign companies that rely on influencers or user-generated content must ensure those materials also comply — ignorance of Chinese law is not a defence.
3. Product Categories Eligible for Post-Filing
The post-filing route (also referred to as “record-filing” or “archival filing”) is a lighter-touch regulatory mechanism. It applies to categories that are deemed lower risk but still warrant administrative oversight. The advertiser self-certifies compliance and files a copy of the advertisement after publication.
3.1 General Cosmetics (普通化妆品)
Since the 2021 cosmetic regulations took full effect, general cosmetics — including moisturisers, cleansers, makeup, and fragrances that do not make therapeutic or sunscreen claims — follow a post-filing process. The advertiser must file the advertisement with the local SAMR office within 7 days of first publication. The SAMR reserves the right to order corrections or suspension within 30 days.
3.2 General Food and Beverages
Ordinary packaged foods, snacks, and non-alcoholic beverages (excluding health foods, infant formula, and FSMP) do not require pre-approval. However, if the advertisement makes any nutrition or health function claim — even a generic reference like “enriched with vitamins” — it may trigger a higher level of scrutiny. Advertisers should still maintain documentation proving all claims.
3.3 Household and Consumer Goods
Cleaning products, home appliances, furniture, clothing, and personal accessories (excluding cosmetics) fall under the post-filing regime. The key requirement is that advertisements must not make unsubstantiated performance claims — for example, claiming a washing machine “kills 99.9% of bacteria” would require a registered disinfection certificate, which itself may reclassify the advertisement under pre-approval.
3.4 Educational and Training Services
Since the “double reduction” (双减) policy of 2021, for-profit academic tutoring for K-9 students is effectively banned from advertising. However, non-academic training (sports, arts, coding) follows a post-filing regime. The advertisement must not imply academic advancement or guarantee examination results.
3.5 Cross-Border E-Commerce (CBEC) Advertising
Products sold through CBEC channels (Tmall Global, JD Worldwide, Kaola) occupy a grey area. While the product itself is not pre-approved by Chinese authorities (the overseas manufacturer retains liability under the law of its home jurisdiction), the advertisement for that product on a Chinese platform is subject to Chinese advertising law. Foreign brands must treat CBEC listing descriptions, A+ content, and promotional videos as subject to post-filing requirements — and in many cases, platforms themselves require pre-publication review as a condition of listing.
Key Takeaway: The post-filing route is not “no compliance.” You must still maintain a complete file of every advertisement, including copies of all claims with supporting evidence, translation certifications, and proof of filing. Failure to file on time can result in administrative penalties of RMB 10,000–100,000.
4. Head-to-Head Comparison: Pre-Approval vs Post-Filing
| Dimension | Pre-Approval Route (审查批准) | Post-Filing Route (事后备案) |
|---|---|---|
| When to submit | Before any publication or broadcast | Within 7–30 days after first publication (varies by province and category) |
| Approval authority | NMPA, SAMR, MARA, or local equivalents depending on category | Local SAMR (county or municipal level) — usually online portal |
| Average processing time | 20–60 working days for standard review; 10–15 working days for simplified review (if eligible) | No review required at time of filing; authority has 30 days to raise objections |
| Validity period | Typically 1 year (must renew; some categories allow 2-year validity) | No expiry — applies to a single advertisement; new filing needed for any material change |
| Documentation burden | High: product registration certificate, safety data, clinical evidence (if applicable), full ad script, storyboard, translations, notarised powers of attorney | Moderate: ad copy, proof of product registration (if applicable), basic company licence, signed compliance self-declaration |
| Cost (government fees) | RMB 2,000–10,000 per ad (varies by category and province); agency fees additional (RMB 8,000–30,000) | Minimal to zero filing fee; agency fees RMB 3,000–8,000 if outsourced |
| Risk of rejection / correction order | 15–25% initial rejection rate for foreign brands (most common reasons: insufficient evidence, non-compliant disclaimers, translation errors) | ~5–10% of filed ads receive correction orders; most are resolved by ad modification within 10 days |
| Penalty for non-compliance | RMB 200,000–1,000,000 fine; possible business licence suspension; advertising ban of up to 1 year for repeat offenders | RMB 10,000–100,000 fine; order to suspend publication; additional penalty for failure to file |
| Best suited for | Pharmaceuticals, medical devices, health foods, special-use cosmetics, infant formula, pesticides | General cosmetics, ordinary foods, household goods, services, CBEC listings, non-academic training |
5. How to Determine Which Route Applies to Your Product
Foreign businesses often struggle to classify their products within China’s regulatory framework because the definitions differ from those in the EU, US, or other Asian markets. Here is a step-by-step decision framework.
Step 1: Classify Your Product Under Chinese Law
Engage a Chinese regulatory consultant or a law firm with a food & drug practice to prepare a formal Product Classification Opinion. This is particularly important for “borderline” products — for example, a collagen drink that a European company might market as a “beauty supplement” but that Chinese authorities could classify as either a health food (pre-approval) or a general food (post-filing). The distinction often comes down to the wording on the label: if the product label makes a functional claim (e.g., “improves skin elasticity”), it likely qualifies as a health food.
Step 2: Identify the Regulating Authority
Once the product is classified, determine which agency has jurisdiction. The matrix is straightforward:
- NMPA → Drugs, medical devices, special-use cosmetics, FSMP
- SAMR → Health foods, general food advertising, general cosmetics, ordinary consumer goods
- MARA → Pesticides, fertilisers, veterinary drugs, feed additives
- National Radio and Television Administration (NRTA) → Broadcast advertisements (TV and radio) — some categories require dual approval from NRTA and the sector-specific authority
Step 3: Assess Whether the Advertisement Makes a “Claim”
Even if your product itself is a general cosmetic or food, if the advertisement makes a health, efficacy, or performance claim, you may be pulled into the pre-approval regime. The key question Chinese authorities ask is: “Does this advertisement assert or imply a benefit that relates to a biological function, disease prevention, or health improvement?” If yes, you likely need pre-approval.
Step 4: Check Provincial Variations
Although the Advertising Law is national, its implementation varies by province. Beijing, Shanghai, and Guangdong — the three largest advertising markets — have more sophisticated digital filing portals and faster processing times. Smaller provinces may require physical submission. Some provinces (e.g., Yunnan for health foods, Sichuan for medical devices) have stricter local standards that effectively require additional documentation beyond what the national law mandates.
When in doubt, submit for pre-approval. The cost and time of an unnecessary pre-approval application is almost always less than the cost of a post-filing correction order, a consumer complaint, or — worst of all — a SAMR investigation triggered by a competitor’s complaint. We have seen foreign brands spend RMB 15,000 on unnecessary pre-approval that saved them a potential RMB 500,000 penalty when a rival filed a complaint with the SAMR three months later.
6. Step-by-Step: Navigating Each Route
6.1 The Pre-Approval Process
- Prepare the dossier. This includes your business licence (notarised and translated), product registration certificate, the full advertisement script (in Chinese), storyboards or mock-ups, supporting evidence for all claims (clinical studies, test reports, certifications), and a letter of authorisation from the product manufacturer.
- Submit via the online portal. Most authorities now use the National Advertising Review System (全国广告审查系统). Digital submissions are strongly preferred; physical submissions are accepted only in a few provinces.
- Respond to queries. The reviewing officer will typically issue 1–3 rounds of questions within 20 working days. Common queries include: “Provide the original clinical trial report in English with a notarised Chinese translation” or “Clarify the difference between ‘moisturising’ and ‘anti-ageing’ in the cosmetic efficacy claim.”
- Receive the approval certificate. The approval number must be displayed in the advertisement. Format varies by category: for drugs it is Guo Yao Guang Xu Zi [Year] No. XXX; for health foods it is Shi Jian Guang Zi [Year] No. XXX.
- Monitor the validity period. Set a calendar reminder to apply for renewal at least 60 days before expiry. Advertising with an expired approval number is treated as unapproved advertising.
6.2 The Post-Filing Process
- Self-certify compliance. Before publication, ensure your advertisement meets all general requirements of the Advertising Law — no false claims, no superlatives like “best” or “first” without evidence, no content that violates social morality or public order.
- Publish the advertisement. You may publish immediately.
- File within the statutory window. Log into the local SAMR filing portal (or submit physically if required). Upload a copy of the advertisement, your business licence, product registration (if applicable), and a signed compliance declaration.
- Keep records. Maintain a filing receipt for each advertisement. This is your proof of compliance in the event of an inspection or complaint.
- Re-file on material change. Any change to the advertisement content — including a revised headline, a new efficacy claim, or a different visual — requires a new filing.
Key Takeaway: Both routes require meticulous record-keeping. Chinese regulators conduct “spot-check” inspections (抽查) of advertisers, and they can request to see the complete compliance file for any advertisement published in the preceding two years. Missing or incomplete records are treated as evidence of non-compliance.
7. Actionable Recommendations for Foreign Enterprises
📋 Strategic Recommendations
- Commission a regulatory classification audit before you localise any marketing materials. A one-time audit costing RMB 15,000–40,000 can prevent compliance missteps that could cost ten times that amount. The audit should cover product classification, advertising route determination, and a review of your existing overseas advertisements for any claims that would be impermissible in China.
- Build a Chinese-language advertising compliance checklist. Every advertisement should be checked against at least 15 criteria: (a) Does it require pre-approval? (b) Does it contain a prohibited superlative? (c) Is the mandatory disclaimer present and correctly formatted? (d) Are all claims supported by verifiable evidence on file? (e) Does it comply with platform-specific rules (e.g., WeChat, Douyin, Tmall)?
- Use a local compliance partner. Even if you have an in-house legal team, a Chinese advertising law specialist who deals with the SAMR daily will flag issues before you submit. Many foreign brands use third-party compliance platforms such as AdComply or China-AdCheck that offer pre-submission review and filing automation.
- For pre-approval products, file early and in batches. Because the approval cycle takes 20–60 days, plan your advertising campaigns at least three months ahead. File multiple advertisements in a single batch to reduce per-unit agency costs. Some agencies offer a “subscription” model where they manage continuous filing for an annual retainer.
- For post-filing products, automate the filing process. Use API-based filing tools that integrate with your content management system. Every time a new advertisement is published on your brand’s WeChat Official Account or Tmall store, the system should automatically file it with the local SAMR portal.
- Monitor regulatory updates quarterly. China’s advertising regulations are updated frequently. The SAMR publishes guidance notes, draft measures, and interpretation letters throughout the year. Subscribe to the SAMR’s English-language bulletin or retain a monitoring service. Notable recent developments include the 2025 digital-advertising-specific guidelines and the tightened rules on AI-generated advertising content (effective Q1 2026).
- Prepare a crisis-response plan. If the SAMR issues a correction order or investigation notice, you typically have only 10 days to respond. Have a pre-approved response template, a designated local legal representative, and a budget for emergency compliance rectification (RMB 20,000–50,000 for a typical correction case).
8. Common Pitfalls and How to Avoid Them
Based on our experience advising over 200 foreign brands on China advertising compliance, the following mistakes recur with alarming frequency:
Pitfall 1: Assuming “Approved Elsewhere” Means “Approved in China”
A cosmetic advertisement that is fully compliant with EU Regulation 1223/2009 may still violate Chinese rules. For example, the EU allows the claim “anti-wrinkle” for certain cosmetic ingredients; in China, “anti-wrinkle” is considered a functional claim that can reclassify a general cosmetic as a special-use cosmetic requiring pre-approval. Fix: Always have a Chinese regulatory consultant review claims from a China-first perspective.
Pitfall 2: Treating E-Commerce Listings as “Different from Advertising”
Product detail pages, A+ content, and listing videos on platforms like Tmall Global are legally advertisements. Multiple foreign brands have received SAMR fines because their cross-border listing included a claim like “clinically proven to improve skin hydration” without supporting evidence filed with Chinese authorities. Fix: Apply the same compliance process to all consumer-facing content.
Pitfall 3: Overlooking Influencer and KOL Content
If your brand pays or incentivises a Chinese influencer (KOL) to promote a product on Xiaohongshu (Little Red Book), Douyin, or Bilibili, that content is an advertisement. Both you and the KOL can be held liable for non-compliance. Since 2024, platforms are required to tag paid promotional content, making it easier for regulators to trace. Fix: Include KOL content in your compliance pre-review and filing process. Provide KOLs with pre-approved scripts.
Pitfall 4: Ignoring the “Three-Month Rule” for Health Foods
For health food advertisements, the SAMR requires that all claims be supported by scientific evidence that has been on file with the authority for at least three months before the advertisement can be approved. This means you cannot rush a health food advertising campaign for a product that has only recently secured its health food registration. Fix: Plan your advertising timeline to include this three-month waiting period.
China’s advertising compliance system is complex but navigable. The key is early classification, meticulous documentation, and a partnership with a knowledgeable local advisor. Whether your product follows the pre-approval or post-filing route, invest the time up front to build a compliant advertising programme — it will protect your brand’s reputation, your market access, and your bottom line.
9. Conclusion
The choice between pre-approval and post-filing is not a strategic preference — it is a legal determination driven by your product category and the specific claims you make in your advertising. For products in high-risk categories (pharmaceuticals, medical devices, health foods, special-use cosmetics, infant formula), the pre-approval route is mandatory and non-negotiable. For lower-risk products (general cosmetics, ordinary foods, household goods, services), the post-filing route offers greater speed and flexibility, but still demands rigorous record-keeping and self-certification.
Foreign enterprises entering China should view advertising compliance not as a burdensome cost but as a competitive advantage. Brands that invest in compliant advertising build trust with Chinese consumers, avoid regulatory disruptions, and differentiate themselves from competitors who cut corners. The SAMR publishes blacklists of non-compliant advertisers — once a brand appears on that list, rebuilding consumer trust is difficult and expensive.
We recommend that every foreign business with plans to market in China conduct a regulatory classification audit before launching any advertising campaign. Determine your route early, build compliance into your creative development process, and maintain a living compliance file for every advertisement you publish. The up-front investment — typically RMB 30,000–80,000 for a full compliance programme — is a fraction of the cost of a single enforcement action.
China’s advertising market is the world’s second largest, with total spending exceeding RMB 1.2 trillion in 2025. For foreign brands that take the time to understand and respect the compliance framework, the opportunities are enormous. This article is a starting point — consult with qualified legal professionals in China for advice tailored to your specific product, category, and advertising strategy.
China Gateway 360 — Article CG360-ADVERTISING-COMP-026.
This article provides general guidance and does not constitute legal advice. Always consult a licensed Chinese attorney for compliance matters.
